{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Temodar+%28Temozolomide%29&page=2", "query": { "intervention": "Temodar (Temozolomide)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Temodar+%28Temozolomide%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T18:50:56.574Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00501891", "title": "Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Metronomic Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2007-07", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00501891" }, { "nct_id": "NCT03535350", "title": "Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-08-24", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03535350" }, { "nct_id": "NCT00734864", "title": "Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Glioma" ], "interventions": [ { "name": "enzyme-inducing anti-epileptic drugs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Annick Desjardins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-06", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2012-11-21", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00734864" }, { "nct_id": "NCT02015728", "title": "Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Childhood Brain Tumor" ], "interventions": [ { "name": "Tumor biology testing", "type": "DEVICE" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Month to 30 Years" }, "enrollment_count": 20, "start_date": "2013-12", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02015728" }, { "nct_id": "NCT03554707", "title": "SGT-53 in Children With Recurrent or Progressive CNS Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Childhood CNS Tumor" ], "interventions": [ { "name": "SGT-53", "type": "GENETIC" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "RADIATION", "DRUG" ], "sponsor": "SynerGene Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 0, "start_date": "2022-06-01", "completion_date": "2022-06-01", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03554707" }, { "nct_id": "NCT01182350", "title": "Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Karen D. Wright MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 53, "start_date": "2011-09", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01182350" }, { "nct_id": "NCT03363659", "title": "Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Disulfiram", "type": "DRUG" }, { "name": "Copper gluconate", "type": "DIETARY_SUPPLEMENT" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-03-28", "completion_date": "2022-01-13", "has_results": true, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03363659" }, { "nct_id": "NCT01076530", "title": "Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Embryonal Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Extra-adrenal Paraganglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Spinal Cord Neoplasm", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 27, "start_date": "2010-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 7, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076530" }, { "nct_id": "NCT07027748", "title": "Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Neuroblastoma Recurrent", "Relapsed Neuroblastoma", "Refractory Neuroblastoma" ], "interventions": [ { "name": "Naxitamab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Sargramostim granulocyte-macrophage colony stimulating factor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Steven DuBois, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 18, "start_date": "2025-06-27", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07027748" }, { "nct_id": "NCT03782415", "title": "Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma", "GBM", "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "MN-166", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MediciNova", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2018-12-29", "completion_date": "2023-08-07", "has_results": false, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-09-29T18:50:56.574Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03782415" } ] }